Evidence map›Paper›PMID 31737685›Full record

ArticleJournal of diabetes research2019

Losartan Reverses Hippocampal Increase of Kynurenic Acid in Type 1 Diabetic Rats: A Novel Procognitive Aspect of Sartan Action.

Iwona Chmiel-Perzyńska, Adam Perzyński, Bartosz Olajossy, Paulina Gil-Kulik, Janusz Kocki, Ewa M Urbańska

Open access · goldAbstract read
In one paragraph

Article in Journal of diabetes research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Kynurenine pathway in kidney diseases.Pharmacological reports : PR · 2022
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Iwona Chmiel-PerzyńskaDepartment of Experimental and Clinical Pharmacology, Medical University in Lublin, Poland.
Adam PerzyńskiII Department of Psychiatry and Psychiatry Rehabilitation, Medical University in Lublin, Poland.
Bartosz OlajossyInternal Medicine and Cardiology Clinic, 1st Military Clinical Hospital in Lublin, Poland.
Paulina Gil-KulikDepartment of Clinical Genetics, Medical University in Lublin, Poland.ORCID https://orcid.org/0000-0003-3119-981X
Janusz KockiDepartment of Clinical Genetics, Medical University in Lublin, Poland.
Ewa M UrbańskaDepartment of Experimental and Clinical Pharmacology, Medical University in Lublin, Poland.ORCID https://orcid.org/0000-0002-2704-528X
Medical University of Lublin · PL1 Military Clinical Hospital with Outpatient Clinic · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with diabetes mellitus (DM) type 1 and 2 are at a higher risk of cognitive decline and dementia; however, the underlying pathology is poorly understood. Kynurenic acid (KYNA), endogenous kynurenine metabolite, displays pleiotropic effects, including a blockade of glutamatergic and cholinergic receptors. Apart from well-known glial origin, kynurenic acid is robustly synthesized in the endothelium and its serum levels correlate with homocysteine, a risk factor for cognitive decline. Studies in an experimental DM model suggest that a selective, hippocampal increase of the kynurenic acid level may be an important factor contributing to diabetes-related cognitive impairment. The aim of this study was to assess the effects of chronic, four-week administration of losartan, angiotensin receptor blocker (ARB), on the brain KYNA in diabetic rats. Chromatographic and rt-PCR techniques were used to measure the level of KYNA and the expression of genes encoding kynurenine aminotransferases, KYNA biosynthetic enzymes, in the hippocampi of rats with streptozotocin-induced DM, treated with losartan. The effect of losartan on KYNA synthesis

Indexed as

Angiotensin II Type 1 Receptor BlockersAnimalsDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1HippocampusHypoglycemic AgentsInsulinKynurenic AcidLosartanMaleNeuroprotective AgentsRatsRats, WistarAngiotensin II Type 1 Receptor BlockersHypoglycemic AgentsInsulinKynurenic AcidLosartanNeuroprotective Agents

Identifiers

PMID31737685
PMCPMC6815597
OpenAlexW2979525871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.